Boehringer ends ‘distraction’ by signing Humira biosimilar deal 15-May-2019 By Ben Hargreaves Boehringer Ingelheim settles litigation with AbbVie over the possible introduction of its Humira biosimilar and agrees a license to market its competitor in 2023.